Pharmaceuticals
Avixgen accelerates the progress on new drug pipeline development
- Pipeline development updates on age related macular degeneration, dry eye disease and atopic dermatitis SEOUL, South Korea, May 24, 2023 /PRNewswire/ -- DxVx has released development updates on the pipelines of its recently acquired company, Avixgen. DxVx acquired about 63% stake of Avixgen, w...
2023-05-24 21:00
2640
BioRay Filed IND Application for BRY812, a Novel Antibody Drug Conjugate Targeting LIV-1
SHANGHAI, May 24, 2023 /PRNewswire/ -- BioRay Pharmaceutical Co., Ltd. (hereinafter referred to as BioRay) announced that the Investigational New Drug (IND) application for the clinical trial of its proprietary BRY812,a novel antibody-drug conjugate (ADC) targeting human LIV-1 for the treatment o...
2023-05-24 16:14
1801
Allgenesis Announces Encouraging Preliminary Safety and Efficacy Data from the AG-73305 Phase 2a Trial for the Treatment of Diabetic Macular Edema
* AG-73305 was found to be safe and tolerable with no severe adverse effects (SAEs) after a single intravitreal injection of 0.5 mg and 1 mg in DME patients. * AG-73305 showed median improvements in Best Corrected Visual Accuity (BCVA) of 8.5 ETDRS letters with median Central Subfield Thickness...
2023-05-24 10:24
1759
PharmAbcine Receives IND Approval from the Korean MFDS for Phase I Clinical Trial of Its Novel TIE2 Agonistic Antibody in nAMD
DAEJEON, South Korea, May 23, 2023 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced today that the Company received IND (Investigational New Drug) approval from the Korean MFDS (Mi...
2023-05-23 20:00
1533
SK bioscience Presents Solution for Equitable Access of Vaccine at Regionalized Vaccine Manufacturing Collaborative of World Economic Forum
* Jaeyong Ahn, CEO of SK bioscience, presents the 'Glocalization' project to secure the global vaccine accessibility, claiming the importance of international cooperation to establish a regional-based vaccine hub at the Regionalized Vaccine Manufacturing Collaborative Side Event. SEONGNAM, Sout...
2023-05-23 20:00
1816
Minghui Pharmaceutical Inc. Announces First-in-Human Dose of MHB018A, a Subcutaneous Single-Domain IGF-1R Antibody in Phase 1a Healthy Volunteer Study
SHANGHAI and HANGZHOU, China and WILMINGTON, Del., May 23, 2023 /PRNewswire/ -- Minghui Pharmaceutical, Inc., a clinical-stage biopharmaceutical company focusing on oncology and autoimmune diseases, today announced that the phase1a trial of MHB018A has commenced with the dosing of its first subje...
2023-05-23 19:00
4554
Antengene Announces Claudin 18.2 Antibody-Drug Conjugate ATG-022 Granted Orphan Drug Designations by the U.S. FDA for the Treatment of Gastric and Pancreatic Cancers
SHANGHAI and HONG KONG, May 23, 2023 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading commercial-stage innovative, global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hemato...
2023-05-23 17:25
2383
HanX Biopharmaceuticals announces HX009 IND approval from FDA
WUHAN, China, May 22, 2023 /PRNewswire/ -- Hanx Biopharmaceuticals, Inc. (HanxBio), announced that the company has received Investigational New Drug (IND) approval to start clinical trial of the potentially first-in-class recombinant anti-CD47/PD-1 bispecific antibody (BsAb), HX009, in Patients w...
2023-05-22 22:00
1792
CSafe Providing Sustainable Thermal Protection for Vyjuvek Gene Therapy from Krystal Biotech
MONROE, Ohio, May 22, 2023 /PRNewswire/ -- CSafe, the largest provider of a complete range of active and passive temperature-controlled shipping solutions for the pharmaceutical industry, is honored to announce an innovative program forKrystal Biotech that provides the cold chain solution for Kry...
2023-05-22 21:23
2660
A random placebo-controlled clinical trial by CU Medicine shows that modulation of gut microbiome using oral microencapsulated live bacteria (SIM01) improves long COVID symptoms
HONG KONG, May 22, 2023 /PRNewswire/ -- 70% of patients in Hong Kong who have recovered from COVID-19continue to suffer from at least one long COVID symptoms at around 6 months. There is however no proven treatment for long COVID. The Chinese University of Hong Kong's (CUHK) Faculty of Medicine (C...
2023-05-22 16:37
2915
WuXi Biologics Receives 2023 ISPE Facility of the Year Award for Operations
DUNDALK, Ireland, May 22, 2023 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced thatthe International Society for Pharmaceutical Engineering (ISPE) has awarded the company a 2023 Facili...
2023-05-22 16:30
2239
Positive Results from Interim Analysis of 'GEN-001' Plus avelumab (Bavencio®) Phase II Trial
* Positive primary endpoint result of objective response rate (ORR) from the planned interim analysis of Phase II trial in advanced gastric/gastroesophageal junction adenocarcinoma (GC/GEJ). * Top-line data of the final analysis from Phase II to be announced in the second half of next year. S...
2023-05-19 21:00
2171
Daewoong Pharmaceutical Presents New Clinical Data of Fexuprazan at Digestive Disease Week 2023
- New investigational data evaluating Fexuprazan in a Korean clinical trial program for healing erosive esophagitis (EE) regardless of food intake, and in a Chinese pivotal clinical trial program for the treatment of EE SEOUL, South Korea and CHICAGO, May 19, 2023 /PRNewswire/ -- Daewoong Pharm...
2023-05-19 20:00
1991
HanAll Biopharma Announces Results from Phase III randomized, double-masked active treatment-controlled VELOS-3 Trial Evaluating Tanfanercept 0.25% for Treatment of Dry Eye Disease
* Tanfanercept did not demonstrate statistical significance in either of the primary outcome measures of improvement in central corneal staining score (CCSS) or in improvement in Eye Dryness Score (EDS) assessed at week 8 in subjects with dry eye disease (DED), compared to vehicle. * However,...
2023-05-19 19:00
1878
Positive Results from Interim Analysis of 'GEN-001' Plus avelumab (Bavencio®) Phase II Trial
SEOUL, South Korea, May 19, 2023 /PRNewswire/ -- Genome & Company (CEO: Pae, Jisoo), a global leading microbiome therapeutics developer, announced that this phase II trial (NCT05419362) will continue without modifications to move on to the second stage, based on the positive result of the interim...
2023-05-19 16:00
1781
EuroPCR 2023 | 6 Month Outcome of the SMART Study: satisfactory BP control achieved with reduced medication burden
PARIS, May 19, 2023 /PRNewswire/ -- On May 17th 2023, the six-month result of the SMART Study (Sympathetic Mapping/Ablation Renal nerves for Treatment of hypertension Trial; NCT02761811) was released on the Late Breaking Clinical Trial conference, reporting ground-breaking findings in the field o...
2023-05-19 14:54
1677
HitGen Announces Drug Discovery Research Agreement with ARase Therapeutics
CHENGDU, China, May 18, 2023 /PRNewswire/ -- Shanghai Stock Exchange listed company HitGen Inc. ("HitGen", SSE: 688222.SH) announced today that it has entered into a research agreement with ARase Therapeutics, Inc. ("ARase"), a biotechnology company developing first-in-class therapeutics targetin...
2023-05-18 21:30
2163
The First of Its Kind in the World: The Recombinant Multivalent COVID-19 Protein Vaccine against XBB Variants by WestVac Biopharma/West China Medical Center, Sichuan University has been Approved for Clinical Trials by The National Medical Products Administration of China.
CHENGDU, China, May 18, 2023 /PRNewswire/ -- On May 17, 2023, Recombinant bivalent COVID-19 protein vaccine (Sf9 cells) and recombinant trivalent COVID-19 trimeric protein vaccine (Sf9 cells) developed by WestVac Biopharma/ West China Medical Center,Sichuan University against the most recent cir...
2023-05-18 21:23
4087
CARsgen Initiates Phase 2 Clinical Trial for CLDN18.2 CAR T-cell Product CT041 in the U.S.
SHANGHAI, May 18, 2023 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced that CARsgen has initiated patient enrollment for Phase 2 of the clinic...
2023-05-18 20:50
2148
YS Biopharma to Participate in the Virtual Benchmark Healthcare House Call Conference on May 23, 2023
GAITHERSBURG, Md., May 18, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseas...
2023-05-18 20:25
3757
Week's Top Stories
Most Reposted
LINKDOOD Breaks Language Barriers, Ushering a New Era for Cross-Border Romance
[Picked up by 326 media titles]
2024-04-29 06:00
Multiple achievements made in China-Hungary BRI conference
[Picked up by 309 media titles]
2024-05-03 06:59
Dow showcases circular and innovative materials science solutions and industry collaborations at Chinaplas 2024
[Picked up by 293 media titles]
2024-04-30 10:11
Xinhua president, Hungarian economy minister vow to bolster media cooperation
[Picked up by 280 media titles]
2024-05-03 06:25Puyuan Fashion Resort 2024: A Grand Unveiling of Global Trends and Local Heritage
[Picked up by 269 media titles]
2024-04-28 09:39
Most Read
Scienjoy Holding Corporation Reports Fiscal Year 2023 Financial Results
2024-04-27 04:30
2965
Ferretti's Dazzling Presence at the 2024 Singapore Yachting Festival: Showcasing Evolving Trends in Luxury Yachting
2024-04-28 15:02
2963
Puyuan Fashion Resort 2024: A Grand Unveiling of Global Trends and Local Heritage
2024-04-28 09:39
2847